C-H Activation: Direct Arylation and Alkenylation of Oxazoles
Dr. Florence MAHUTEAU (INSTITUT CURIE, ORSAY, France)
10:05
Coffee-break
10:45
Orally Active, Brain Penetrant Beta-Secretase (BACE) Inhibitors: Consolidating Property-Based and Structure-Based Drug Design
Dr. Stephen HITCHCOCK (AMGEN INC, Thousand Oaks, United States)
11:25
From Structures to Systems: Structure Based Design of Therapeutics and Imaging Probes
Dr. Ulrich WENDT (SANOFI AVENTIS, Frankfurt, Germany)
12:05
Structure-Activity Relationships and Cancer-Cell Selective Toxicity Of Novel Inhibitors of Glioma-Associated Oncogene Homolog 1 (Gli1)-Mediated Transcription
Dr Naoaki FUJII (ST.JUDE CHILDREN'S RESEARCH HOSPITAL, Memphis, United States)
12:20
Molecular Recognition at the Active Site of Catechol-O-Methyl Transferase (COMT): Energetically Favorable Expulsion of a Single Water Molecule with Novel Bisubstrate Inhibitors.
Mr Manuel ELLERMANN (ETH ZURICH, Zurich, Switzerland)
Discovery of Ixempratm (ixabepilone), an Epothilone Analogue for Treatment of Metastatic Breast Cancer
Dr. Gregory VITE (BMS, Princeton, United States)
15:20
Design and Synthesis of Novel Polyketide Molecular Frameworks to Access Natural Product-Like Protein-Protein Interaction Inhibitors as Novel Chemotherapeutic Agents
Dr Giovanna ZINZALLA (CANCER RESEARCH UK - THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON, London, United Kingdom)
15:35
Coffee-break and Poster Session 1
16:05
Compound Collection Enhancement (CCE): Increasing Quality and Size of the AZ Compound Collection
Dr. Kay BRICKMANN (ASTRA ZENECA, Mölndal, Sweden)
16:45
Approach to the Synthesis of Pycnanthuquinone C by Gold(I)-Catalyzed Cyclization of 1,5-Enynes
Ms NURIA HUGUET (INSTITUTE OF CHEMICAL RESEARCH OF CATALONIA, Tarragona, Spain)
17:25
C-H: A New Functional Group for Streamlining Synthesis
Case Histories of Fragment Based Discovery: from Crystal to Clinic
Dr David REES (ASTEX THERAPEUTICS, Cambridge, United Kingdom)
09:50
Design and synthesis of polyfluoroalkyl-containing purine isosters and phospha-purines as a potential Adenosine Deaminase (ADA) and Inosine 5’-monophosphate dehydrogenase (IMPDH) inhibitors
Dr Dmytro VOLOCHNYUK (ENAMINE, Kyiv, Ukraine)
10:05
Coffee-break and Poster Session 1
10:45
The Fight against AIDS. The "Old" Reverse Transcriptase (RT) and the "New"
DDX3
